194 related articles for article (PubMed ID: 27090116)
1. Adherence to Long-Term Interferon Beta-1b Injection Therapy in Patients with Multiple Sclerosis Using an Electronic Diary.
Zettl UK; Bauer-Steinhusen U; Glaser T; Czekalla J; Hechenbichler K; Limmroth V; Hecker M
Adv Ther; 2016 May; 33(5):834-47. PubMed ID: 27090116
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of an electronic diary for improvement of adherence to interferon beta-1b in patients with multiple sclerosis: design and baseline results of an observational cohort study.
Zettl UK; Bauer-Steinhusen U; Glaser T; Hechenbichler K; Limmroth V;
BMC Neurol; 2013 Sep; 13():117. PubMed ID: 24011220
[TBL] [Abstract][Full Text] [Related]
3. Adherence, satisfaction and functional health status among patients with multiple sclerosis using the BETACONNECT® autoinjector: a prospective observational cohort study.
Kleiter I; Lang M; Jeske J; Norenberg C; Stollfuß B; Schürks M
BMC Neurol; 2017 Sep; 17(1):174. PubMed ID: 28877664
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Medication Adherence Using a Medical App Among Patients With Multiple Sclerosis Treated With Interferon Beta-1b: Pilot Digital Observational Study (PROmyBETAapp).
Limmroth V; Hechenbichler K; Müller C; Schürks M
J Med Internet Res; 2019 Jul; 21(7):e14373. PubMed ID: 31359863
[TBL] [Abstract][Full Text] [Related]
5. The impact of betaplus program on patient treatment satisfaction with interferon beta-1b in multiple sclerosis: Multicentric cross-sectional survey in the western Balkan countries.
Drulovic J; Cukic M; Grgic S; Dincic E; Raicevic R; Nadj C; Toncev G; Vojinovic S; Mesaros S; Kisic Tepavcevic D; Dujmovic I; Tadic D; Miletic-Drakulic S; Dackovic J; Kostic S; Erakovic J; Sakalas L; Savic D; Suknjaja V; Martinovic V; Maric G; Pekmezovic T
Mult Scler Relat Disord; 2017 Jan; 11():56-61. PubMed ID: 28104258
[TBL] [Abstract][Full Text] [Related]
6. Patient satisfaction with ExtaviPro™ 30G, a new auto-injector for administering interferon β-1b in multiple sclerosis: results from a real-world, observational EXCHANGE study.
Hoffmann FA; Trenova A; Llaneza MA; Fischer J; Lus G; von Bredow D; Lara N; Lam E; Van Hoef M; Bakshi R
BMC Neurol; 2017 Aug; 17(1):156. PubMed ID: 28793876
[TBL] [Abstract][Full Text] [Related]
7. Comparison of injection site pain and injection site reactions in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a or 1b.
Baum K; O'Leary C; Coret Ferrer F; Klímová E; Procházková L; Bugge J;
Mult Scler; 2007 Nov; 13(9):1153-60. PubMed ID: 17967843
[TBL] [Abstract][Full Text] [Related]
8. Interferon beta-1b (betaseron/betaferon) is well tolerated at a dose of 500 microg: interferon dose escalation assessment of safety (IDEAS).
Gottesman MH; Friedman-Urevich S
Mult Scler; 2006 Jun; 12(3):271-80. PubMed ID: 16764339
[TBL] [Abstract][Full Text] [Related]
9. Multiple sclerosis patients treated with intramuscular IFN-β-1a autoinjector in a real-world setting: prospective evaluation of treatment persistence, adherence, quality of life and satisfaction.
Hupperts R; Becker V; Friedrich J; Gobbi C; Salgado AV; Sperling B; You X
Expert Opin Drug Deliv; 2015 Jan; 12(1):15-25. PubMed ID: 25430947
[TBL] [Abstract][Full Text] [Related]
10. Subjective patient-reported versus objective adherence to subcutaneous interferon β-1a in multiple sclerosis using RebiSmart®: the CORE study.
Zecca C; Disanto G; Mühl S; Gobbi C
BMC Neurol; 2017 Sep; 17(1):171. PubMed ID: 28870152
[TBL] [Abstract][Full Text] [Related]
11. Baseline predictors of persistence to first disease-modifying treatment in multiple sclerosis.
Zettl UK; Schreiber H; Bauer-Steinhusen U; Glaser T; Hechenbichler K; Hecker M;
Acta Neurol Scand; 2017 Aug; 136(2):116-121. PubMed ID: 27796033
[TBL] [Abstract][Full Text] [Related]
12. Adherence to Subcutaneous IFN β-1a in Multiple Sclerosis: Final Analysis of the Non-Interventional Study READOUTsmart Using the Dosing Log and Readout Function of RebiSmart
Rieckmann P; Schwab M; Pöhlau D; Penner IK; Wagner T; Schel E; Bayas A
Adv Ther; 2019 Jan; 36(1):175-186. PubMed ID: 30488338
[TBL] [Abstract][Full Text] [Related]
13. Adherence to interferon β-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV study.
Devonshire VA; Feinstein A; Moriarty P
BMC Res Notes; 2016 Mar; 9():148. PubMed ID: 26951043
[TBL] [Abstract][Full Text] [Related]
14. Morphea secondary to interferon beta1b injection: a case and review of the literature.
Ozlu E; Karadag AS; Akdeniz N; Uzuncakmak TK; Zemheri E; Ozkanli S
Dermatol Online J; 2019 Apr; 25(4):. PubMed ID: 31046913
[TBL] [Abstract][Full Text] [Related]
15. Supportive strategies to improve adherence to IFN β-1b in multiple sclerosis--results of the βPlus observational cohort study.
Pozzilli C; Schweikert B; Ecari U; Oentrich W;
J Neurol Sci; 2011 Aug; 307(1-2):120-6. PubMed ID: 21636099
[TBL] [Abstract][Full Text] [Related]
16. Assessment of adherence to, and persistence with, an electromechanical autoinjector for subcutaneous interferon beta-1a injections for multiple sclerosis treatment over 3 years.
Piras F; Arnaud L; Henninger E; Keiser M; Seitzinger A; Jack D; Le Masne Q
Expert Opin Drug Deliv; 2023 Jun; 20(6):863-870. PubMed ID: 37273189
[TBL] [Abstract][Full Text] [Related]
17. Injection anxiety remains a long-term barrier to medication adherence in multiple sclerosis.
Turner AP; Williams RM; Sloan AP; Haselkorn JK
Rehabil Psychol; 2009 Feb; 54(1):116-21. PubMed ID: 19618711
[TBL] [Abstract][Full Text] [Related]
18. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis.
Reynolds MW; Stephen R; Seaman C; Rajagopalan K
Curr Med Res Opin; 2010 Mar; 26(3):663-74. PubMed ID: 20070144
[TBL] [Abstract][Full Text] [Related]
19. Long-term adherence of patients with relapsing-remitting multiple sclerosis to subcutaneous self-injections of interferon β-1a using an electronic device: the RIVER study.
Lugaresi A; De Robertis F; Clerico M; Brescia Morra V; Centonze D; Borghesan S; Maniscalco GT;
Expert Opin Drug Deliv; 2016 Jul; 13(7):931-5. PubMed ID: 26909646
[TBL] [Abstract][Full Text] [Related]
20. Adherence and persistence to drug therapies for multiple sclerosis: A population-based study.
Evans C; Marrie RA; Zhu F; Leung S; Lu X; Melesse DY; Kingwell E; Zhao Y; Tremlett H
Mult Scler Relat Disord; 2016 Jul; 8():78-85. PubMed ID: 27456879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
